? Cancer Center Administration Abramson Cancer Center (ACC) Administration is responsible for supporting the ACC, an internationally renowned, NCI-Designated Comprehensive Cancer Center, in the management of resources and services required to facilitate the scientific mission of reducing the burden of cancer. These activities include strategic planning, evaluation, and decision-making; governance and management of the fiscal and administrative components of multiple ACC- and Cancer Center Support Grant (CCSG)-related activities; and management of Shared Resources, membership, the CCSG application, research and grant administration, and events and communication. Administration coordinates with other ACC activities (Community Outreach and Engagement, and Cancer Research Training and Education Coordination) as well as other support offices in the ACC, such as: Clinical Protocol and Data Management (CPDM)'s Department of Operations, Compliance and Monitoring; Development; and the Office of Legal Affairs. It represents the Center within the parent Institution and to the NCI and other external entities. The challenge of executing these priorities in a complex matrix cancer center requires Administration to have the talent, experience, and expertise necessary to support multiple constituent priorities (both internal and external), while maintaining dedication to their mission. ACC Administration comprises a cohesive group of highly experienced staff with the demonstrated proficiency necessary to skillfully meet the needs of ACC members, who accomplished unprecedented growth and success in the past decade. These key administrative staff members have clearly defined roles and responsibilities, with appropriate reporting lines both internally and within the larger Penn Medicine institution, to ensure that the administrative activities of the ACC are delivered in an effective and efficient manner.
Specific aims are to: 1) Administratively lead in the governance and decision-making processes of the ACC; 2) Deliver efficient and effective professional administrative oversight, financial management, and non-administrative and regulatory guidance to support cancer research activities, including all activities specifically related to the CCSG; and 3) Represent the interests of the ACC both within the parent Institution and with external groups, to ensure the Center adheres to, and helps shape, policies that govern its activities.
|Raposo-Ferreira, Talita M M; Brisson, Becky K; Durham, Amy C et al. (2018) Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 55:622-633|
|Kasner, Margaret T; Mick, Rosemarie; Jeschke, Grace R et al. (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36:657-666|
|Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970|
|Huffman, Austin P; Richman, Lee P; Crisalli, Lisa et al. (2018) Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 24:594-599|
|Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542|
|Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32|
|Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318|
|Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :|
|Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:|
|Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215|
Showing the most recent 10 out of 1047 publications